Prostate Cancer Screening in Men With Germline BRCA2 Mutations

NCT02154672 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1

Last updated 2021-02-09

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the incidence of prostate cancer in men with the BRCa2 gene mutation as an independent indicator for prostate cancer screening.

Conditions

Sponsors & Collaborators

  • Yale University

    lead OTHER

Principal Investigators

  • Preston Sprenkle, MD · Yale University

Eligibility

Min Age
30 Years
Max Age
90 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-31
Primary Completion
2019-11-01
Completion
2019-11-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02154672 on ClinicalTrials.gov